Dr. Curtis Miyamoto, MD

Dr. Miyamoto practices at Temple University Hospital - Main Campus in Philadelphia, Pennsylvania.

Dr. Miyamoto's NPI, 1144246117, was assigned on July 14, 2006. Dr. Miyamoto graduated from Hahnemann University College of Medicine in 1991. Dr. Miyamoto holds Pennsylvania license MD041050L.

Dr. Miyamoto's primary practice is Temple University Hospital - Main Campus, at 3401-41 N Broad St, Philadelphia, PA 19140 in Philadelphia County. The practice phone is (215) 707-5303.

Dr. Miyamoto's primary practice is Temple University Hospital - Main Campus in Philadelphia, Pennsylvania. Dr. Miyamoto is also affiliated with Temple University Hospital. The medical group on file is Temple Faculty Physicians. Dmand AI also links Dr. Miyamoto to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Miyamoto practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Miyamoto's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Miyamoto is licensed in Pennsylvania.

CMS data shows 839 Medicare services from Dr. Miyamoto across 13 procedure codes in 2024, for 140 Medicare patients. Medicare paid $52,472 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 140 Medicare patients who saw Dr. Miyamoto in 2024. The largest group is 65 to 74, with 73 patients. 75% of them have cancer, and 75% have high blood pressure. 37% are also on Medicaid. Their average risk score is 2.33, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Miyamoto's median patient age at 70, with 37% women.

In 2024, Dr. Miyamoto wrote 191 Medicare Part D claims for 65 patients. 100% of them were for generic drugs. CMS names the drug for 133 of them, across 4 drugs with 11 or more claims each, at $2,150 in total drug cost. In 2023, CMS named 88 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Miyamoto for performance year 2024, reported as part of a group. Dr. Miyamoto accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 16 papers to Dr. Miyamoto, published from 2011 to 2023. 2011 was the busiest year, with 4. The most frequent topics are Radiosurgery, Radiotherapy Dosage and Radiotherapy, Image-Guided. Dr. Miyamoto's most frequent co-authors are Bizhan Micaily, MD, Vladimir Valakh, MD and Enrique Hernandez, MD.

Dmand AI links Dr. Miyamoto to 2 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Cognitive Dysfunction, Meningioma and Cognition Disorders. NRG Oncology sponsors the most, 2.

CMS Open Payments shows 2 general payments to Dr. Miyamoto from 2 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. Elekta, Inc. paid the most, $30.

Dr. Miyamoto graduated from Hahnemann University College of Medicine in 1991.